Market Cap 686.55M
Revenue (ttm) 170.44M
Net Income (ttm) -193.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -113.75%
Debt to Equity Ratio 0.00
Volume 3,298,700
Avg Vol 2,044,648
Day's Range N/A - N/A
Shares Out 51.70M
Stochastic %K 85%
Beta 0.90
Analysts Strong Sell
Price Target $24.36

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
rando321456
rando321456 Jul. 4 at 3:00 AM
$RGNX Thinking outloud I think there's a pretty good chance subretinal 314 prices at 100k+ assuming it showcases results in line what has been observed so far.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 2:36 PM
The $XBI is up 24.5% the last 15 trading sessions (since 6/10/2026). Investors may recall 4 years ago this time when the XBI surged 31.6% between 6/14/22 & 7/6/22. Excluding the market recovery during COVID in 2020, there's only 2 other times the XBI surged like this (15 day period ending 1/16/19 & before Thanksgiving back in 16). The XBI is almost at its record high. It traded at over $160 for 11 days back in early 2021 Recall it was May 12, 2026 when Dr. Makary resigned. Since then the FDA has reversed course on a number of bio's potential. Attached are the biggest gainers over the last 15 days (60% of more). $RGNX has overwhelmingly been the biggest winner now that they will refile for Navsunli approval in Q326. $SLS doubled again. Short interest is 36% per Seeking Alpha. At a $3B market cap SLS trades @ 4.3X Year 4 (FY30) revenue (from 1 analyst). We though we were smart when we sold SLS in the mid $4 range back in January. $DFTX reported its P3 win 6/22/26 $MRNA we have friends there :)
0 · Reply
opsiyon
opsiyon Jul. 3 at 6:21 AM
0 · Reply
Bioze
Bioze Jul. 3 at 3:40 AM
$RGNX 💪
0 · Reply
FigBar36
FigBar36 Jul. 2 at 11:16 PM
$RGNX holding since 5.69, and will continue. Who’s going to join me?
2 · Reply
topstockalerts
topstockalerts Jul. 2 at 9:30 PM
$RGNX the stock keeps finding fresh footing.
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 3:46 PM
0 · Reply
SegiBagholder2026
SegiBagholder2026 Jul. 2 at 2:02 PM
$RGNX THEY JUST GOT 100M!
0 · Reply
SEC_LIARS
SEC_LIARS Jul. 2 at 2:00 PM
$RGNX Eaaaaaasy to hold👍👍
0 · Reply
Ml55totoag
Ml55totoag Jul. 2 at 12:42 PM
$RGNX Steve believes the opposite of what he says?
2 · Reply
Latest News on RGNX
Regenxbio completes dosing in confirmatory study of RGX-202

2026-06-24T11:10:54.000Z - 10 days ago

Regenxbio completes dosing in confirmatory study of RGX-202


Regenxbio price target raised to $32 from $27 at Baird

2026-06-23T10:44:38.000Z - 11 days ago

Regenxbio price target raised to $32 from $27 at Baird


Regenxbio aligns with FDA on path forward for Navsunli

2026-06-22T11:41:10.000Z - 12 days ago

Regenxbio aligns with FDA on path forward for Navsunli


REGENXBIO to Participate in Upcoming Investor Conferences

May 18, 2026, 4:05 PM EDT - 6 weeks ago

REGENXBIO to Participate in Upcoming Investor Conferences


Regenxbio price target lowered to $14 from $25 at BofA

2026-05-15T10:40:05.000Z - 7 weeks ago

Regenxbio price target lowered to $14 from $25 at BofA


Regenxbio price target lowered to $12 from $37 at Barclays

2026-05-15T09:10:09.000Z - 7 weeks ago

Regenxbio price target lowered to $12 from $37 at Barclays


REGENXBIO Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 7 weeks ago

REGENXBIO Earnings release: Q1 2026


REGENXBIO Quarterly report: Q1 2026

May 14, 2026, 9:30 AM EDT - 7 weeks ago

REGENXBIO Quarterly report: Q1 2026


Regenxbio reports Q1 EPS ($1.72) vs. 12c last year

2026-05-14T13:02:06.000Z - 7 weeks ago

Regenxbio reports Q1 EPS ($1.72) vs. 12c last year


REGENXBIO Transcript: Study result

May 14, 2026, 8:00 AM EDT - 7 weeks ago

REGENXBIO Transcript: Study result


REGENXBIO Press release: Study result

May 14, 2026, 8:00 AM EDT - 7 weeks ago

REGENXBIO Press release: Study result


REGENXBIO Slides: Study result

May 14, 2026, 8:00 AM EDT - 7 weeks ago

REGENXBIO Slides: Study result


REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Proxy statement: Proxy filing


REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Proxy statement: Proxy filing


REGENXBIO Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 3 months ago

REGENXBIO Proxy statement: Proxy filing


REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 4 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026


REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

REGENXBIO Earnings Call Transcript: Q4 2025


REGENXBIO Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

REGENXBIO Annual report: Q4 2025


REGENXBIO Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

REGENXBIO Earnings release: Q4 2025


US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 5 months ago

US FDA declines to approve Regenxbio's rare disease drug


REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 5 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II


US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 5 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials


REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 28, 2026, 7:30 AM EST - 5 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs


REGENXBIO Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 6 months ago

REGENXBIO Slides: Corporate presentation


REGENXBIO Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 7 months ago

REGENXBIO Registration statement: Registration Filing


REGENXBIO to Participate in Upcoming Investor Conference

Nov 25, 2025, 7:05 AM EST - 7 months ago

REGENXBIO to Participate in Upcoming Investor Conference


REGENXBIO Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 1:20 PM EST - 8 months ago

REGENXBIO Transcript: Stifel 2025 Healthcare Conference


REGENXBIO Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

REGENXBIO Earnings Call Transcript: Q3 2025


REGENXBIO Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

REGENXBIO Quarterly report: Q3 2025


REGENXBIO Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

REGENXBIO Earnings release: Q3 2025


REGENXBIO Announces Presentation at the World Muscle Society

Sep 29, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO Announces Presentation at the World Muscle Society


rando321456
rando321456 Jul. 4 at 3:00 AM
$RGNX Thinking outloud I think there's a pretty good chance subretinal 314 prices at 100k+ assuming it showcases results in line what has been observed so far.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 2:36 PM
The $XBI is up 24.5% the last 15 trading sessions (since 6/10/2026). Investors may recall 4 years ago this time when the XBI surged 31.6% between 6/14/22 & 7/6/22. Excluding the market recovery during COVID in 2020, there's only 2 other times the XBI surged like this (15 day period ending 1/16/19 & before Thanksgiving back in 16). The XBI is almost at its record high. It traded at over $160 for 11 days back in early 2021 Recall it was May 12, 2026 when Dr. Makary resigned. Since then the FDA has reversed course on a number of bio's potential. Attached are the biggest gainers over the last 15 days (60% of more). $RGNX has overwhelmingly been the biggest winner now that they will refile for Navsunli approval in Q326. $SLS doubled again. Short interest is 36% per Seeking Alpha. At a $3B market cap SLS trades @ 4.3X Year 4 (FY30) revenue (from 1 analyst). We though we were smart when we sold SLS in the mid $4 range back in January. $DFTX reported its P3 win 6/22/26 $MRNA we have friends there :)
0 · Reply
opsiyon
opsiyon Jul. 3 at 6:21 AM
0 · Reply
Bioze
Bioze Jul. 3 at 3:40 AM
$RGNX 💪
0 · Reply
FigBar36
FigBar36 Jul. 2 at 11:16 PM
$RGNX holding since 5.69, and will continue. Who’s going to join me?
2 · Reply
topstockalerts
topstockalerts Jul. 2 at 9:30 PM
$RGNX the stock keeps finding fresh footing.
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 3:46 PM
0 · Reply
SegiBagholder2026
SegiBagholder2026 Jul. 2 at 2:02 PM
$RGNX THEY JUST GOT 100M!
0 · Reply
SEC_LIARS
SEC_LIARS Jul. 2 at 2:00 PM
$RGNX Eaaaaaasy to hold👍👍
0 · Reply
Ml55totoag
Ml55totoag Jul. 2 at 12:42 PM
$RGNX Steve believes the opposite of what he says?
2 · Reply
Enodloca
Enodloca Jul. 2 at 10:53 AM
0 · Reply
Dont_believe_pumper
Dont_believe_pumper Jul. 2 at 6:23 AM
$RGNX I need some serious advise . Where this is heading for ? Is it bubble only or you see the price rising to 16-17 dollars ? I need serious analysis ?
2 · Reply
StockScanners
StockScanners Jul. 2 at 4:04 AM
$RGNX keep watch if this holds above 12.96
0 · Reply
topstockalerts
topstockalerts Jul. 2 at 12:53 AM
$RGNX this advance feels both calm and determined.
1 · Reply
Hoganknowsbest
Hoganknowsbest Jul. 1 at 10:48 PM
$RGNX how is this up and Srpt down on good news and profitable company. And capr down with FDA approval coming in 6 weeks. Fucking joke.
3 · Reply
BioRich
BioRich Jul. 1 at 6:31 PM
$RGNX Not a bad month and a half on this wounded duck. Seems to be full steam ahead again. Hope folks were able to start a position low or DCA down to recover losses for longs. Looking for $UNCY to have a similar recovery as they navigate their own FDA recovery path. Time will tell, but congrats to $RGNX folks. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
BioRich
BioRich Jul. 1 at 4:44 PM
$NKTR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) $VVOS 33) $RGNX 35) $ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
makingdoughfromoptions
makingdoughfromoptions Jul. 1 at 4:29 PM
$RGNX Given the reversal for Huntington's by FDA, Abbvie deep pockets to fund P3 trials, etc. I would not begin to sell shares under $50-. Let's see how this plays out, will take a few years. Up to 5 to max out your income.
0 · Reply
buymoremakemore
buymoremakemore Jul. 1 at 4:18 PM
$RGNX fall 2026. FDA approves RGX-121 $20+ stock. 2B BO. Lets go
0 · Reply
Teillbou
Teillbou Jul. 1 at 3:47 PM
$RGNX crazy spicy today !
0 · Reply
SEC_LIARS
SEC_LIARS Jul. 1 at 3:34 PM
$RGNX Eeeeeasy to hold since 9.5👍👍
0 · Reply
Lanikai16
Lanikai16 Jul. 1 at 3:24 PM
$RGNX make an offer $ABBV
0 · Reply